Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Keiko Inakami"'
Autor:
Keiko Inakami, Noriko Fujita, Chikage Iguchi, Yukie Enomoto, Junya Minohata, Atsushi Sata, Yoshimasa Miyagawa, Tetsu Yanagisawa, Tomokazu Saitoh, Takashi Nomura, Yuka Sawai, Keiko Takahara, Tsutomu Kasugai, Eiichi Shiba
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-6 (2024)
Abstract Background Pembrolizumab (PEM), an immune checkpoint inhibitor (ICI), is often used for triple-negative breast cancer, but can also be used to treat solid tumors that exhibit high microsatellite instability (MSI-High). However, patients with
Externí odkaz:
https://doaj.org/article/20aff28844e8466f92c48eee2fbc960b
Autor:
Nao Imai, Mika Kitayama, Akiko Shibahara, Yuri Bessho, Mai Shibusawa, Aya Noro, Keiko Inakami, Noriko Hanamura, Hiroshi Imai, Tomoko Ogawa
Publikováno v:
Asian Journal of Surgery, Vol 42, Iss 1, Pp 228-234 (2019)
Summary: Background: After the ACOSOG Z0011 trial, it became important to evaluate the number of metastatic axillary lymph nodes (LNs) preoperatively. The purpose of this paper is to confirm whether the number of metastases can be accurately diagnose
Externí odkaz:
https://doaj.org/article/3990002bb7dd4114abd9d75eb1f0b495
Autor:
Noriko Fujita, Koichi Fujita, Seung Jin Kim, Chikage Iguchi, Takashi Nomura, Toyokazu Aono, Tetsu Yanagisawa, Yukie Enomoto, Keiko Inakami, Yoshimasa Miyagawa, Riki Tomoike, Tsutomu Kasugai, Eiichi Shiba
Publikováno v:
Oncology. 100(5)
Background: De-escalation therapy omitting anthracycline has been generally adopted for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the adjuvant setting, but not in the neoadjuvant chemotherapy (NAC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e97363e49de72424728d0a75ead5d3f
https://pubmed.ncbi.nlm.nih.gov/35114682
https://pubmed.ncbi.nlm.nih.gov/35114682
Autor:
Chikage Iguchi, Eiichi Shiba, Noriko Fujita, Keiko Inakami, Hitoshi Yamamoto, Tsutomu Kasugai, Takashi Nomura, Tetsu Yanagisawa, Yukie Enomoto, Toyokazu Aono
Publikováno v:
Oncology. 98:35-41
Background: It is unclear for whom new anti-human epidermal growth factor receptor 2 (anti-HER2) agents, such as pertuzumab and T-DM1, should be considered. We investigated prognostic factors before neoadjuvant chemotherapy (NAC) among HER2-positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::123600771ad0d0f73f58d5e52db70b3b
https://doi.org/10.1159/000502910
https://doi.org/10.1159/000502910